Rescheduling Arrives: Real Change or Just a New Label?

Editor's Brief

The DOJ's final cannabis rescheduling order dropped this week, and the industry is already stress-testing what it actually means. Spoiler: it's complicated. From Georgia expanding medical access to Indiana prepping a 2027 legalization push, the state-level dominoes keep falling — with or without Washington's leadership.

Meanwhile, the market is sending mixed signals. Michigan sales are sliding, Target is stocking THC beverages in three states, and Oklahoma is forcing cannabis companies to register with the DEA under the new Schedule III framework. Today's edition connects all the dots.

Top Story

Cannabis Rescheduling Is Official — Here's What It Actually Changes

The Department of Justice's final order moving cannabis from Schedule I to Schedule III is now on the books. Reuters calls it a landmark moment — and it is — but the fine print matters enormously. Schedule III status covers medical and research use only, meaning recreational cannabis remains federally illegal in every state where it's been legalized.

Trump's Drug Czar, ONDCP director Sara Carter Bailey, didn't mince words on Newsmax: "It's still illegal." She pivoted quickly to concerns about THC potency, foreign grows, and hemp-derived THC — signaling that the administration's posture is far from permissive. NORML's op-ed this morning echoes the frustration, arguing reclassification was "long overdue, but still not enough."

The practical fallout is already hitting operators. Oklahoma's Bureau of Narcotics is now requiring medical cannabis manufacturers and distributors to register with the DEA — a direct consequence of Schedule III compliance requirements. Expect other medical-state regulators to follow. For the industry, this means new federal paperwork, new compliance costs, and an uncomfortable new relationship with federal drug enforcement.

For home growers and consumers, the symbolic shift matters less than the structural gaps it leaves behind. Banking reform, interstate commerce, and expungement remain unresolved. Watch Congress — particularly whether the VA medical marijuana amendment survives its upcoming floor vote — for the next real signal of how far federal reform will actually go.

Policy & Legalization

Georgia Expands Medical Program

Governor Brian Kemp signed SB 220 into law, meaningfully broadening Georgia's medical marijuana program. The bill adds new qualifying conditions, legalizes vaporizing cannabis, and adjusts THC potency limits. It's a modest but real win for patients in a state that has historically offered one of the most restrictive medical frameworks in the South.

VA Veterans' Amendment Advances to House Floor

A bipartisan amendment from Reps. Brian Mast (R-FL) and Dave Joyce (R-OH) cleared committee and heads to a full House floor vote. It would allow VA doctors to recommend medical cannabis to veterans — a significant policy shift given how many vets rely on cannabis for PTSD, chronic pain, and TBI management. Passage is not guaranteed, but the committee clearance alone is progress.

Indiana Preps 2027 Medical Cannabis Bill

An Indiana lawmaker is already drafting a medical cannabis legalization bill for the 2027 legislative session. Indiana remains one of the few states with zero cannabis access, making this a notable shift in political momentum. The 2027 timeline reflects how slowly change moves in conservative-leaning legislatures — but the groundwork is being laid now.

Business & Markets

Michigan Sales Continue to Slide

April cannabis sales in Michigan hit $258.6 million — down 4.3% year-over-year, though up slightly from March. Medical sales cratered 24.1% from a year ago, now a rounding error at $0.4 million. Michigan's adult-use market remains fiercely price-competitive, and the persistent year-over-year decline signals the state's market is still working through oversupply and price compression.

Target Goes THC in Three States

Retail giant Target is rolling out intoxicating hemp-derived THC beverages in Florida, Texas, and Illinois — covering more than 300 store locations. This is a massive mainstream retail moment for hemp-derived cannabinoids. It also intensifies the regulatory pressure Congress is feeling to crack down on unregulated hemp products, which surfaced in today's Marijuana Moment newsletter.

Arizona Repeal Campaign Folds

The campaign to repeal Arizona's adult-use cannabis market officially shut down after its organizer, Sean Noble of American Encore, said his views on the industry's impact on kids had changed. Arizona's legal market survives what would have been a rare voter-driven rollback. It's a quiet but meaningful victory for legalization advocates — and a reminder that public opinion on cannabis keeps shifting in one direction.

Science & Cultivation

Older First-Time Buyers Prefer CBD-THC Combos

A new study in JAMA Network Open analyzed first-time cannabis buyers aged 60+ in Colorado and found they gravitated toward CBD-only or combined CBD/THC products over THC-only options. The findings come from University of Utah Intermountain Health researchers and reinforce what dispensary budtenders have long observed. Older consumers want therapeutic benefit without intensity — a clear signal for product developers and cultivators selecting genetics.

Cannabis and Stress: Gen Z's New Normal

Fresh Toast reports that cannabis is increasingly being used by Gen Z to manage stress, anxiety, and digital burnout — with expert backing. The pattern mirrors what we saw with millennials and alcohol, but cannabis is becoming the preferred tool for younger consumers. For growers, this suggests sustained demand for calming, anxiety-focused cultivars — think high-myrcene, high-CBD balanced strains.

Culture & Community

Puff and Chess: Where Cannabis Meets the Royal Game

Sam Adler is running "Puff and Chess" events across New York City — get high, learn chess, drop your guard. His father reviewed records for High Times in the 1970s. His mother hosts a PBS cooking show. It's a genuinely good hang, and it's exactly the kind of community event that builds the normalization cannabis advocates have worked toward for decades.

Cannabis Creators vs. The Algorithm

High Times digs into the ongoing war cannabis creators are waging against social media censorship — using code words like "broccoli" to evade platform bans. Accounts are still being lost regularly, but a growing playbook of workarounds is keeping the community alive online. It's absurd, it's creative, and it's very cannabis.

What This Means for Growers

• Schedule III compliance is coming for commercial operators. If you're a licensed medical cannabis producer, expect DEA registration requirements to land at your door — budget time and legal fees accordingly.
• Demand for balanced CBD/THC genetics is rising. The JAMA study on older consumers confirms a market shift. Breeders and home growers selecting for therapeutic effects over raw THC potency are ahead of the curve.
• Calming, stress-relief cultivars have a growing audience. Gen Z's embrace of cannabis for anxiety and burnout points to sustained demand for high-myrcene, linalool-forward, and CBD-inclusive genetics.
• Hemp-derived THC competition is intensifying. Target putting THC beverages on shelves in 300+ stores signals the hemp market is eating into regulated cannabis territory. Know your product's differentiation.
• Federal reform remains incomplete — plan accordingly. Rescheduling doesn't fix banking, interstate commerce, or home grow protections. Keep your compliance house in order and don't assume the federal environment is suddenly friendly.

Quick Links

Full source links are listed below this article.